Hypermarcas (OTCMKTS:HYPMY) Short Interest Up 12,687.5% in June

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 2,046 shares, a growth of 12,687.5% from the June 15th total of 16 shares. Based on an average trading volume of 33,339 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy”.

Get Hypermarcas alerts:

Check Out Our Latest Stock Report on HYPMY

Hypermarcas Trading Up 3.3%

Shares of Hypermarcas stock traded up $0.13 during trading on Friday, reaching $4.09. The company’s stock had a trading volume of 2,969 shares, compared to its average volume of 24,426. The company has a 50-day moving average price of $4.28 and a two-hundred day moving average price of $4.39. The firm has a market cap of $2.88 billion, a PE ratio of 8.52 and a beta of 0.71. Hypermarcas has a fifty-two week low of $3.71 and a fifty-two week high of $5.50.

Hypermarcas (OTCMKTS:HYPMY – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.10 EPS for the quarter. The firm had revenue of $383.13 million during the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. On average, analysts predict that Hypermarcas will post 0.53 earnings per share for the current fiscal year.

Hypermarcas Company Profile

(Get Free Report)

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.

Featured Articles

• Five stocks we like better than Hypermarcas
• AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
• Micron’s $250 Billion Bet Could Reshape the AI Memory Race
• Rocket Lab’s Stock Drop Comes With a Bullish Twist
• Amazon’s New Debt Deal Puts Its AI Spending Story on Trial

Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.